Mylan, a generics and specialty pharmaceutical company based in Canonsburg, Penn., will expand its operations in Dublin and Galway, Ireland, by investing up to $100 million over the next five years.

The investment will fund expanded R&D and manufacturing capabilities within the company's respiratory, injectables and oral solids franchises. In addition, with support from the Irish Development Authority (IDA), Myland will add more than 500 new positions to its Ireland-based workforce by 2016.

"The expansion of Mylan's operations in Ireland is an extremely positive development for Ireland's life sciences sector,” said Barry O'Leary, CEO of IDA. “These projects meet with key objectives of IDA Ireland's strategy Horizon 2020 to create high quality life sciences jobs. I wish Mylan every success with this operation and on behalf of IDA Ireland look forward to continuing to work closely and support the company in the future.''

Mylan's operations in Ireland include Gerard Laboratories and Bioniche Pharma.